Clinical trial · Observational
Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA)
Clinical Follow-up of Patients Treated With Radiofrequency Ablation of Lung Masses.
NCT00641238CI-TRIAL-00072318completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We are collecting clinical notes and results of imaging studies (CT and PET scans) from referring physicians who follow the clinical status of patients treated with radiofrequency ablation (RFA). The research objective is to determine whether the patients with (RFA) remain alive, and whether they are in remission or have progressive/ recurrent malignancy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiofrequency ablation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Early stage NSCLC
- description
- Early stage non-small cell lung cancer
- interventionNames
- Device: Radiofrequency ablation
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 5 years after diagnosis of NSCLC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with lung masses * Patients who consent to radiofrequency ablation of mass
References
Publications (0)
Data not yet available
No reference posted for this study.